Pharmacy Independent Prescribing Income 2026: How to Account for the New £525 Fee

The introduction of NHS funded independent prescribing into community pharmacy in England is the most structurally significant new income stream to enter the Community Pharmacy Contractual Framework since Pharmacy First launched in 2024. Confirmed as part of the 2026/27 CPCF settlement announced on 29 May 2026, pharmacists who hold an independent prescribing qualification will be able to assess patients and prescribe medicines directly, building on the success of the Pharmacy First service.

For community pharmacy owners, the service raises immediate and practical financial management questions that go beyond the headline announcement. What exactly is the payment structure? When does the income start flowing? How should it be recognised in your management accounts? What are the VAT implications of a new NHS commissioned prescribing service? How does it interact with your Pharmacy First fixed payment threshold? What are the allowable expenses associated with setting up and running the service? And critically, given that the service is optional, how do you model whether participation is financially worthwhile for your specific pharmacy?

This guide answers all of those questions. It is written specifically for pharmacy owners managing the financial transition into independent prescribing, not a clinical guide, but a financial management and accounting guide for one of the most significant new income opportunities in community pharmacy in years.

What Independent Prescribing in Community Pharmacy Actually Means

Before addressing the financial management questions, it is worth being precise about what the service involves and who can deliver it, because the eligibility and operating conditions directly affect the financial model.

From September 2026, all newly qualified pharmacists will enter the General Pharmaceutical Council register as independent prescribers on the day of their registration. For pharmacies employing recently qualified pharmacists, this means a growing proportion of the workforce will hold the IP qualification automatically from September 2026 onwards without any additional training requirement.

For existing pharmacists who qualified before September 2026, the IP qualification must be obtained through a separate postgraduate programme, typically a 26 week course delivered by a higher education institution and involving a period of supervised practice. The cost of this training varies by provider but is typically in the range of £1,500 to £3,000 per pharmacist.

Under the 2026/27 CPCF, pharmacy prescribers will be able to prescribe within the existing Pharmacy First clinical pathways and the Pharmacy Contraception Service. The nationwide rollout is from Autumn 2026. The scheme commenced in June 2026 and it will continue to be an optional part of the CPCF. It will be down to pharmacy owners to decide on an individual basis whether they want to provide the service or prioritise the use of IP skills elsewhere in their business.

The optionality is important for financial planning purposes. Unlike the Pharmacy First establishment payment, which is paid to all commissioned pharmacies regardless of consultation volume, the IP infrastructure payment is not automatic. Pharmacy owners must actively choose to participate and sign up through the appropriate commissioning process before income begins to flow.

The IP Payment Structure: Exactly What You Will Receive

The IP income stream under the 2026/27 CPCF has three distinct components, each of which has different payment mechanics, different accounting treatment, and different cash flow timing.

Component 1: The One Off £500 Set Up Payment

The initial introduction of independent prescribing during 2026/27 will be funded through a one off £500 set up fee, payable once a contractor has signed up to deliver the relevant service.

This is a capital style commissioning payment paid once, at the point of signing up to deliver the service. It is not a recurring annual payment. It is a single contribution toward the cost of establishing IP capability in your pharmacy. For accounting purposes, this payment should be recognised as income in the period in which the sign up is completed and the entitlement arises, not deferred across the year.

The £500 set up payment is modest relative to the actual cost of establishing IP capability, particularly where existing pharmacists require postgraduate training. A pharmacist completing an IP training course at a cost of £2,500 generates a net initial investment of £2,000 after the set up payment, a cost that is recoverable through the ongoing monthly infrastructure payments over time.

Component 2: The £525 Monthly Infrastructure Payment

There will be a monthly infrastructure payment of £525 in addition to the usual Pharmacy First or PCS consultation fees.

This is the financially most significant element of the IP income stream. At £525 per month, the annual infrastructure payment for a pharmacy participating in the IP service for a full year is £6,300. This payment is received regardless of the volume of IP consultations delivered in the month. It is a fixed monthly payment for maintaining IP capability and being commissioned to deliver the service.

For accounting purposes, the £525 monthly infrastructure payment should be recognised monthly as it is earned, accrued if the cash has not yet arrived from NHSBSA, and separately identified in your management accounts nominal codes. It must not be combined with Pharmacy First consultation fees or the Pharmacy First establishment payment. It is a distinct income stream from a distinct service component.

Component 3: Per Consultation Fees at Existing Pathway Rates

Consultation fees for prescribing consultations within existing pathways will align with those received for a patient group direction consultation, £17 for Pharmacy First clinical pathways, £25 for an initiation or ongoing contraception consultation, and £20 for an emergency hormonal contraception consultation.

These per consultation fees are paid at the same rates as standard Pharmacy First and PCS consultations. IP does not attract a higher per consultation rate. The financial benefit of IP is therefore not in the per consultation fee but in the expanded range of conditions that can be treated, the expanded medicines that can be prescribed within those pathways, and the monthly infrastructure payment that is paid on top of whatever consultation volume is achieved.

Component 4: IP Consultations Count Toward the Fixed Payment Threshold

The Pharmacy First fixed payment arrangements for clinical pathways will be maintained, with new IP clinical pathway consultations counting towards fixed payment thresholds. Fixed payments will remain at £500 for contractors delivering 20 to 29 consultations in a month and £1,000 for those delivering 30 consultations or more.

This is a significant financial benefit that is easily overlooked. A pharmacy that was previously delivering 25 standard Pharmacy First consultations per month, earning the £500 fixed payment, and adds 10 IP consultations now delivers 35 total qualifying consultations. This tips them from the £500 fixed payment to the £1,000 fixed payment, an additional £500 per month, or £6,000 per year, from the fixed payment mechanism alone. The IP consultations effectively subsidise an uplift in the fixed payment tier.

Financial modelling point: Before deciding whether to participate in the IP service, model your current Pharmacy First consultation volumes and assess whether adding IP consultations would take you from one fixed payment tier to the next. For a pharmacy consistently delivering 18 to 25 consultations per month, adding IP consultations to cross the 20 consultation or 30 consultation threshold generates income from the fixed payment change that is additional to the monthly infrastructure payment and the per consultation fees.

The Full Income Model: What IP Could Generate for Your Pharmacy

To illustrate the financial impact, here is a worked example for a pharmacy that signs up in Autumn 2026 and delivers a modest volume of IP consultations.

Pharmacy profile: Single site, existing Pharmacy First provider delivering 22 consultations per month across standard clinical pathways. Currently receives £500 fixed payment per month plus £17 per consultation = £500 + (22 × £17) = £874 per month from Pharmacy First.

After adding IP, scenario with 10 IP consultations per month:

Total Pharmacy First and IP consultations: 22 + 10 = 32 per month, crosses the 30 consultation threshold.

Fixed payment: increases from £500 to £1,000 per month, additional £500 per month.

IP consultation fees (10 × £17): £170 per month, assuming Pharmacy First clinical pathway.

IP monthly infrastructure payment: £525 per month.

One off set up payment: £500, received once on sign up.

Additional monthly income from IP: £500 + £170 + £525 = £1,195 per month.

Additional annual income from IP: £14,340 plus the one off £500 set up payment.

Against this, the costs of participation include: pharmacist training where required, time allocated to IP consultations within existing staffing, any premises modifications, and administrative time to manage the IP claim process through NHSBSA.

For a pharmacy where the superintendent pharmacist already holds the IP qualification, or where a member of staff is approaching qualification, the ongoing cost of delivering the service is primarily an opportunity cost of time rather than a direct cash expenditure. For pharmacies that need to fund training, the payback period on a £2,500 training cost at £1,195 per month of additional income is approximately two months.

Accounting for IP Income: Setting Up Your Nominal Codes Correctly

Getting the accounting structure right from the first month of IP income is more important than it might initially appear. Combining IP income with standard Pharmacy First income in a single nominal code creates management accounts that cannot answer the most basic question your accountant or bank manager will ask: how much does each service line contribute to your pharmacy’s profitability?

The correct nominal code structure for a pharmacy operating Pharmacy First and IP from June 2026 is:

Pharmacy First consultation fees: separate nominal code for the per consultation income from standard Pharmacy First clinical pathway consultations (£17 per consultation)

Pharmacy First fixed payment: separate nominal code for the monthly fixed payment (£500 or £1,000 depending on threshold)

IP consultation fees: separate nominal code for per consultation fees from IP clinical pathway consultations (£17, £25, or £20 depending on the pathway)

IP monthly infrastructure payment: separate nominal code for the £525 monthly payment

IP set up payment: separate nominal code for the one off £500 commissioning payment, or include as a sub item within the IP infrastructure code with a note that it is non recurring

NHS SAF income: existing code for the Single Activity Fee at £1.52 per item

Pharmacy Contraception Service: existing code for PCS consultation fees

This level of nominal separation allows you to produce management accounts that show the financial contribution of each commissioned service independently, which is essential both for your own planning and for demonstrating to commissioners that the service is being delivered at adequate volume. Our bookkeeping for healthcare team sets up the correct nominal structure for all pharmacy clients introducing IP from the service launch date.

VAT Treatment of Independent Prescribing Income

The VAT treatment of IP consultation income follows the same analysis as standard Pharmacy First consultations. NHS commissioned clinical services delivered by a registered pharmacist in the course of their profession are exempt from VAT under Group 7 of Schedule 9 to the Value Added Tax Act 1994, the healthcare exemption.

The IP consultation fees, the monthly infrastructure payment, and the set up payment are all NHS commissioned healthcare services delivered by a registered healthcare professional. They are all VAT exempt.

This means you do not charge VAT on IP income, and patients, or the NHS, do not pay VAT on IP consultations. For the majority of pharmacies that are not VAT registered, this is straightforward. For VAT registered pharmacies with a partial exemption position, typically those with significant cosmetic or standard rated private income, the IP income joins the exempt income pool and does not affect the taxable supply numerator in the partial exemption recovery ratio.

One practical consequence: if you are purchasing equipment or undertaking premises modifications specifically to enable IP delivery, a dedicated consultation room, clinical assessment equipment, prescription printing capability, the VAT on those costs is not recoverable as input tax because the service they support is exempt. This cost should be factored into the financial model for IP service setup.

If you are uncertain about the VAT position of your pharmacy’s IP income in the context of your existing partial exemption arrangement, our VAT specialist team can review and confirm the correct treatment before you begin making claims.

The Expense Side: What IP Delivery Costs and What Is Allowable

The financial modelling for IP must account for the costs of delivering the service as well as the income it generates. The allowable expenses associated with IP delivery are straightforward.

IP Training Costs

Where you fund the IP training of an employed pharmacist, the full cost of the training course, typically £1,500 to £3,000, is a deductible business expense. Training costs that enable staff to expand their role in your pharmacy are legitimate business expenditure. The £500 set up payment partially offsets this cost in year one.

Where a pharmacist funds their own IP training independently of the pharmacy, for example where a locum or self employed pharmacist obtains the qualification at their own expense, that individual can claim the training cost as an allowable expense on their own Self Assessment return, as it is a cost of maintaining and expanding their professional competence.

Premises Costs

Where IP delivery requires a dedicated consultation room or modifications to existing consultation facilities, additional seating, clinical equipment, soundproofing for patient privacy, the capital cost of those modifications may qualify for capital allowances. Fixtures and fittings in the consultation room qualify for the Annual Investment Allowance, giving 100% tax relief in the year of expenditure. As covered in our capital allowances guide, the AIA limit is £1,000,000, well above any consultation room fit out cost a community pharmacy is likely to incur.

Clinical Equipment and Consumables

Clinical assessment equipment purchased for IP delivery, blood pressure monitors, peak flow meters, point of care testing equipment, qualifies as plant and machinery for capital allowances purposes. Consumable clinical materials used in IP consultations, testing strips, PPE, consumable supplies, are deductible as revenue expenditure in the period they are used.

Pharmacist Time and Staffing Costs

The time your IP qualified pharmacist spends on IP consultations is already covered by their salary. There is no separate reimbursement for pharmacist time above the consultation fees and infrastructure payment. Where IP delivery requires additional staffing cover to free up the IP pharmacist’s time, locum cover while the IP pharmacist conducts consultations, for example, that additional staffing cost is a deductible business expense. Factor this into your financial model, particularly if your pharmacy is small enough that IP consultations require backfilling the dispensary.

The Pharmacy Quality Scheme 2026/27: What Has Been Confirmed

For the first time in recent years, the PQS for 2026/27 has been confirmed alongside the main CPCF settlement. A revised Pharmacy Quality Scheme will be introduced in June for 2026/27 with a value of £20 million.

Pharmacy owners that choose to participate will be able to claim in July an aspiration payment of 80% (up from 75% last year) of the overall points value they intend to claim.

This earlier confirmation and the increased aspiration payment rate are both improvements on previous years, allowing better cash flow planning and earlier receipt of PQS income. For pharmacy owners who include PQS in their annual income budget, the confirmed £20 million scheme value and June commencement should be reflected in your 2026/27 management accounts from June onwards rather than being deferred until confirmation later in the year.

The PQS aspiration payment, 80% of intended claim value, is received in July 2026. The balance is payable on achievement of the criteria. For accounting purposes, the aspiration payment should be accrued as income when the entitlement arises on submission of the aspiration claim and the balance accrued as and when achievement is confirmed.

The NHSBSA Reconciliation Process for IP Income

IP consultation income flows through NHSBSA using the same Electronic Prescription Service infrastructure as standard Pharmacy First consultations. The monthly infrastructure payment and the one off set up payment are administered separately through the NHSBSA payment schedule.

Understanding the payment timing is important for cash flow management. Monthly consultation fees, both standard Pharmacy First and IP, are typically paid two to three months in arrears via the NHSBSA payment schedule. The monthly infrastructure payment of £525 should be tracked separately on the schedule and verified each month.

As with all NHSBSA income, your monthly payment schedule is the primary document for reconciliation. Each line item, SAF income, Pharmacy First consultation fees, IP consultation fees, IP infrastructure payment, PCS fees, NMS fees, should be checked against your own records of the services delivered. Errors in NHSBSA payment schedules occur and are most frequently identified through rigorous monthly reconciliation. Our pharmacy accounting team reconciles NHSBSA payment schedules monthly for all pharmacy clients, ensuring IP income is correctly captured from the first month of delivery.

For further detail on the reconciliation process across all NHS income streams including clawback management, our pharmacy NHS dispensing income guide covers the full mechanics of the NHSBSA payment and reconciliation cycle.

Should Your Pharmacy Participate? The Financial Decision Framework

The IP service is optional. The decision to participate is a business decision that should be made on the basis of a clear financial model specific to your pharmacy, not on the basis of the sector wide announcement or the headline income figures.

Factors That Make IP Participation Financially Attractive

Your pharmacy already has one or more IP qualified pharmacists on staff. The ongoing cost of delivery is absorbed into existing salary costs with no additional training expenditure.

Your Pharmacy First consultation volumes sit near the 20 or 30 consultation threshold. Adding IP consultations tips you into a higher fixed payment band, generating additional income beyond the IP specific payments.

Your pharmacy has a suitable consultation room already in use for Pharmacy First. No premises investment is required to begin IP delivery.

Your local ICB has strong appetite for commissioned IP services. Demand for IP consultations is likely to be higher where ICB support for the service is active.

Factors That Make the Financial Case Weaker

No current pharmacist holds the IP qualification and training costs of £2,500 per pharmacist are required before the service can launch.

Your pharmacy is staffing constrained. IP consultations require a pharmacist’s undivided attention, and in a small pharmacy this may require locum cover that costs more than the IP income generated.

Your Pharmacy First volumes are comfortably in one threshold band with no realistic prospect of crossing to the next through IP addition.

Your premises do not include a suitable private consultation room. Investment in fit out is required before the service can launch.

The financially disciplined approach is to model your specific pharmacy’s position across all of these variables before committing to participation, rather than treating the headline income figures as representative of your pharmacy’s actual net position.